Study on Dynamic Changes of Serum IGF-1 Post-Cerebral Hemorrhage and Its Prognostic Correlation

NCT07043504 | Not Yet Recruiting DMC

• 1 other identifier: 2025PS1176K(X1)
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to dynamically observe the dynamic changes of serum IGF-1 after intracerebral hemorrhage, explore the impact and correlation of serum IGF-1 with the severity of the patient's condition and prognosis, and provide a reference for clinical treatment timing.

Conditions

Insulin-Like Growth Factor I

Keywords

Intracerebral Hemorrhage; Prognosis; IGF-1

Outcome Measures

Primary Outcomes (1)

• The relationship between serum IGF-1 levels within 3 days after intracerebral hemorrhage and the severity of the condition (referring to NIHSS score)

  Serum IGF-1 levels decrease in the acute phase after intracerebral hemorrhage, and the decrease is correlated with the severity of the condition. (The more severe the condition, the larger the number of patients with reduced IGF-1 levels, and the more significant the decrease in IGF-1 values.)，The higher the IGF-1 level, the lower the NIHSS score.

  3 days after intracerebral

Secondary Outcomes (1)

• The correlation between the dynamic change trend of IGF-1 after intracerebral hemorrhage and the prognosis of patients

  The 5th month

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with intracerebral hemorrhage from Shengjing Hospital Affiliated to China Medical University and those from Northern Theater General Hospital

You may qualify if:

• Aged 18 to 75 years old;
• Patients with intracerebral hemorrhage (NIHSS ≥5 points);
• No history of cerebrovascular diseases with residual functional impairment before brain injury;
• Hospitalized within 72 hours after injury;
• BMI ≤28.

You may not qualify if:

• Patients with severe cardiac, hepatic, renal, or pulmonary dysfunction;
• Glycated hemoglobin \>9.0% at screening;
• History of hypothalamic-pituitary related diseases or severe endocrine diseases;
• Use of drugs affecting endocrine function (such as glucocorticoids, growth hormones) within the past six months;
• Pregnant patients. -

Sponsors & Collaborators

• Shengjing Hospital: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood

MeSH Terms

Conditions

Cerebral Hemorrhage

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

YanMei Yin, Master

CONTACT

18940259354; yym15998315189@163.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Yin Yanmei

Study Record Dates

• First Submitted: June 21, 2025
• First Posted: June 29, 2025
• Study Start: July 1, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: June 29, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share